CN104688695B - 一种含有伏立康唑的药物组合物 - Google Patents
一种含有伏立康唑的药物组合物 Download PDFInfo
- Publication number
- CN104688695B CN104688695B CN201310640886.1A CN201310640886A CN104688695B CN 104688695 B CN104688695 B CN 104688695B CN 201310640886 A CN201310640886 A CN 201310640886A CN 104688695 B CN104688695 B CN 104688695B
- Authority
- CN
- China
- Prior art keywords
- voriconazole
- mesh sieves
- weight
- pharmaceutical composition
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 title claims abstract description 56
- 229960004740 voriconazole Drugs 0.000 title claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 239000000945 filler Substances 0.000 claims abstract description 12
- 239000007884 disintegrant Substances 0.000 claims abstract description 9
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 40
- 229920002472 Starch Polymers 0.000 claims description 28
- 235000019698 starch Nutrition 0.000 claims description 28
- 239000008107 starch Substances 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 20
- 239000000741 silica gel Substances 0.000 claims description 20
- 229910002027 silica gel Inorganic materials 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 15
- 229910052708 sodium Inorganic materials 0.000 claims description 15
- 239000000853 adhesive Substances 0.000 claims description 14
- 230000001070 adhesive effect Effects 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 13
- 238000007873 sieving Methods 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000004703 cross-linked polyethylene Substances 0.000 claims description 2
- 229920003020 cross-linked polyethylene Polymers 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 abstract description 48
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 abstract description 25
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 abstract description 24
- 229960003415 propylparaben Drugs 0.000 abstract description 24
- 238000004090 dissolution Methods 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 24
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 24
- 238000000034 method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000013558 reference substance Substances 0.000 description 9
- 239000012535 impurity Substances 0.000 description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- XCHRPVARHBCFMJ-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-yl)ethanone Chemical compound FC1=CC(F)=CC=C1C(=O)CN1N=CN=C1 XCHRPVARHBCFMJ-UHFFFAOYSA-N 0.000 description 1
- UHOPWFKONJYLCF-UHFFFAOYSA-N 2-(2-sulfanylethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCS)C(=O)C2=C1 UHOPWFKONJYLCF-UHFFFAOYSA-N 0.000 description 1
- AYZDRTRWCASUFO-UHFFFAOYSA-N 4-ethyl-5-fluoropyrimidine Chemical compound CCC1=NC=NC=C1F AYZDRTRWCASUFO-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 241000132889 Scedosporium Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310640886.1A CN104688695B (zh) | 2013-12-04 | 2013-12-04 | 一种含有伏立康唑的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310640886.1A CN104688695B (zh) | 2013-12-04 | 2013-12-04 | 一种含有伏立康唑的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104688695A CN104688695A (zh) | 2015-06-10 |
CN104688695B true CN104688695B (zh) | 2017-11-10 |
Family
ID=53336529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310640886.1A Active CN104688695B (zh) | 2013-12-04 | 2013-12-04 | 一种含有伏立康唑的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104688695B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108186581B (zh) * | 2018-02-11 | 2021-08-31 | 海南锦瑞制药有限公司 | 一种伏立康唑制剂及其制备方法 |
CN115518046B (zh) * | 2021-06-26 | 2024-02-06 | 扬子江药业集团南京海陵药业有限公司 | 一种伏立康唑分散片及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101390861A (zh) * | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | 一种含有伏立康唑的固体药物组合物 |
CN102133202A (zh) * | 2011-03-08 | 2011-07-27 | 浙江华海药业股份有限公司 | 一种含有伏立康唑的片剂 |
EP2409699A1 (en) * | 2010-07-23 | 2012-01-25 | Combino Pharm, S.L. | Stable compositions of voriconazole |
CN102885774A (zh) * | 2011-07-18 | 2013-01-23 | 李勤耕 | 普拉格雷组合物及其制备方法 |
-
2013
- 2013-12-04 CN CN201310640886.1A patent/CN104688695B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101390861A (zh) * | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | 一种含有伏立康唑的固体药物组合物 |
EP2409699A1 (en) * | 2010-07-23 | 2012-01-25 | Combino Pharm, S.L. | Stable compositions of voriconazole |
CN102133202A (zh) * | 2011-03-08 | 2011-07-27 | 浙江华海药业股份有限公司 | 一种含有伏立康唑的片剂 |
CN102885774A (zh) * | 2011-07-18 | 2013-01-23 | 李勤耕 | 普拉格雷组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
尼泊金酯类和富马酸酯类抑菌效果的研究;袁海涛,等;《食品科技》;20010531(第5期);第43-44页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104688695A (zh) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA517390473B1 (ar) | أشكال جرعة صلبة من بالبوسيكليب | |
EA017764B1 (ru) | Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием | |
TW201000472A (en) | New solid pharmaceutical formulations comprising BIBW 2992 | |
CN102266307B (zh) | 一种缬沙坦胶囊及其制备方法 | |
CN102499923A (zh) | 一种药物组合物、其制备方法及用途 | |
RU2661402C2 (ru) | Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата | |
CN104688695B (zh) | 一种含有伏立康唑的药物组合物 | |
CN104586804B (zh) | 一种稳定性好的来曲唑片的制备方法 | |
CN104840427B (zh) | 一种含有孟鲁司特钠的药物组合物 | |
CN109953966A (zh) | 一种含有瑞博西尼的药物组合物及其制备方法 | |
CN103948553A (zh) | 一种拉莫三嗪缓释片及其制备方法 | |
CN103191065A (zh) | 塞来昔布新剂型及其制备方法 | |
CN105030711A (zh) | 一种阿齐沙坦片剂的制备方法 | |
CN104415036B (zh) | 一种含有苯磺酸氨氯地平的药物组合物 | |
CN104840460B (zh) | 一种含有缬沙坦和氨氯地平的药物组合物 | |
KR20120138521A (ko) | 카르두스 마리아누스 엑스, 및 쿠르쿠마 잔토리자 엑스를 포함하는 필름코팅정, 및 이의 제조방법 | |
CN104352465B (zh) | 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法 | |
CN104398482B (zh) | 应用复合乳糖的吲达帕胺缓释药物 | |
CN104688696B (zh) | 一种含有坎地沙坦酯的药物组合物 | |
Pujara et al. | Formulation and evaluation of hard gelatin capsule of losartan potassium | |
CN106880597A (zh) | 一种依维莫司片 | |
CN103989645B (zh) | 一种孟鲁司特钠片剂及其制备方法 | |
CN112691084A (zh) | 一种药物组合物及其制备方法 | |
Yadav et al. | Development of Doxazosin mesylate liquisolid system for improved manufacturing processability and bioavailability: in vitro and in vivo evaluation for tailored hypertension treatment approach with modified dissolution rates | |
CN104435119B (zh) | 五味子总木脂素有效部位固体分散体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination containing voriconazole Effective date of registration: 20231226 Granted publication date: 20171110 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000149 |